Part 2: Easter Island, Pit Vipers; Where do drugs come from?
Part 3: Vacuum Cleaners that make Sir James Dyson Weep
Ashutosh Jogelekar (Scientific American)
Continuation of the series.
The [Monsanto] GMO Suicide Myth
Keith Kloor (Discover Magazine)
Making a Difference in NHL and CLL: an Interview with Dr. Carol Gallagher
Sally Church (Pharma Strategy Blog)
5 Key Points on Immune Checkpoint Inhibitors for Lung Cancer: Game Changer or Just Leveling Up?
Jack West (Cancer GRACE)
Clinical development success rates for investigational drugs
Michael Hay, David W Thomas, John L Craighead, Celia Economides & Jesse Rosenthal
Nature Biotechnology 32, 40–51 (2014) doi:10.1038/nbt.2786 [9 January 2014]
A New Look at Clinical Attrition
Derek Lowe (In the Pipeline)
“Saving the winners” to improve pharma R&D
Frank David (Pharmagellan)
The latest look at the data on the who-what-when-where-why-how of drug candidates failing on the road to FDA approval. Links to the Nature Biotechnology paper and two perspectives on it.
The Big Guys Have Lost Their Iron Grip, and It’s All Good
Luke Timmerman (Xconomy)
FirstWord Lists – The drugs that will shape 2014
Simon King (FirstWord Pharma)
Social Media & Cancer Drugs: Conversation, not Promotion
Laura Strong (The Next Element)